YvetteSawtell2 at 12:06, 19 February 2026

2026-02-19T12:06:38Z

New page

{{Short description|Indian pharmaceutical company}}
{{Use dmy dates|date=March 2023}}
{{Use Indian English|date=March 2023}}
{{Infobox company
| name = Emcure Pharmaceuticals Limited
| logo = Emcure Pharmaceuticals.svg
| logo_alt = Logo of Emcure Pharmaceuticals Limited
| image_caption = Company Logo
| type = [[Public company|Public]]
| traded_as = {{ubl|{{NSE|EMCURE}}|{{BSE|544210}}}}
| area_served = Worldwide
| ISIN = {{ISIN|sl=n|pl=y|INE168P01015}}
| industry = [[Pharmaceutical]]
| products =
| revenue = {{increase}} {{INRconvert|7963|c}} (2025)
| operating_income = {{increase}} {{INRconvert|981|c}} (2025)
| net_income = {{increase}} {{INRconvert|707|c}} (2025)
| num_employees = 11,000+ (January 2022)<ref name="Revenue">{{cite news |title=Emcure Pharma's Rs 5,000-crore IPO to hit market early next month |url=https://www.business-standard.com/article/companies/emcure-pharma-s-rs-5-000-crore-ipo-to-hit-market-early-next-month-122012001429_1.html |access-date=3 January 2023 |work=Business Standard |date=20 January 2022 |language=en}}</ref>
| parent =
| subsid =
| homepage = {{URL|https://emcure.com}}
| foundation = {{Start date and age|1981}}<ref name="crisil">{{cite news |title=Emcure Pharmaceuticals Limited |url=https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/EmcurePharmaceuticalsLimited_January%2028,%202022_RR_286031.html |access-date=3 January 2023 |work=CRISIL}}</ref>
| founder = Satish Mehta
| key_people = {{ubl|Satish Mehta ([[Chief executive officer|CEO]] & [[Managing director|MD]]) |Berjis Desai (Chairman)<ref>{{cite news |title=Emcure Pharma inducts 4 independent directors |url=https://www.thehindu.com/business/emcure-pharma-inducts-4-independent-directors/article35570362.ece |access-date=7 February 2023 |work=The Hindu |date=27 July 2021 |language=en-IN}}</ref>|Sunil Mehta ([[Executive Director]])|[[Namita Thapar]] ([[Executive Director]])<ref>{{Cite web|title=Shark Tank India Season 2: New shark joins the gang|url=https://www.livemint.com/news/india/shark-tank-india-season-2-new-shark-joins-the-gang-watch-11667319853750.html|access-date=2022-11-02|date=2022-11-01|website=Mint|language=en-US}}</ref>}}
| location = [[Hinjawadi]], [[Pune]], India
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref>{{cite web |title=Quarter and Year end Financials FY25 |url=https://www.emcure.com/wp-content/uploads/2025/05/Quarter-and-Year-end-Financials-FY25.pdf |publisher=Emcure Pharmaceuticals |access-date=27 May 2025}}</ref>
}}

'''Emcure Pharmaceuticals Limited (Emcure)''' is an Indian multinational [[Pharmaceutical industry|pharmaceutical]] company, headquartered in [[Pune]]. Emcure's product portfolio includes [[Tablet (pharmacy)|tablets]], [[Capsule (pharmacy)|capsules]] (both [[softgel]] capsules and hard-gel capsules) and injectables.<ref>{{Cite web|title=Emcure Pharmaceuticals {{!}} Leading Global Pharmaceutical Company|url=https://www.emcure.com/|access-date=2021-08-23|website=Emcure|language=en-US}}</ref><ref>{{Cite web|title=Emcure Pharmaceuticals|url=https://economictimes.indiatimes.com/topic/Emcure-Pharmaceuticals|access-date=2021-08-23|website=The Economic Times}}</ref> The company produces [[gynaecology]], [[cardiovascular]], [[oncology]] and [[blood]] [[therapeutic drugs]], [[HIV]] [[Antiviral drug|antivirals]] and other [[Infection prevention and control|anti-infectives]], and [[Dietary supplement|vitamins and minerals]].<ref name="Revenue"/><ref>{{cite web |title=Emcure Pharmaceuticals Ltd |url=https://www.bloomberg.com/profile/company/763195Z:IN |website=Bloomberg |access-date=28 June 2024}}</ref>

== History ==
Emcure Pharmaceuticals was established in 1981 by Satish Mehta, who began the company with a bank loan of {{INR}}3 [[lakh]] (about US$35,000 then) after graduating from [[Indian Institute of Management Ahmedabad|IIM-A]].<ref>{{cite news |last1=Thakur |first1=Gaurav |title=A cure from Mr Mehta |url=https://timesofindia.indiatimes.com/pune-times/a-cure-from-mr-mehta/articleshow/254639.cms |access-date=3 July 2024 |work=The Times of India |date=28 October 2003}}</ref> In the 1990s, the company transitioned from being a [[contract manufacturing organization]] to a producer of [[generic drug]]s.<ref>{{cite web |title=Satish Mehta & family |url=https://www.forbes.com/profile/satish-mehta-1/ |website=Forbes |access-date=10 July 2024 |language=en}}</ref>

In 2006, Emcure signed license agreements with [[Bristol-Myers Squibb]] for [[Atazanavir]]<ref>{{Cite news|url=https://www.business-standard.com/article/Companies/Bristol-Myers-outsources-AIDS-drug-to-Emcure-106021701143_1.html|title=Bristol-Myers outsources AIDS drug to Emcure|publisher=Business Standard| newspaper=Business Standard India |date=17 February 2006}}</ref> and [[Gilead Sciences]] for [[Tenofovir]] as part of their Global Access Programs.<ref>{{cite news |title=Gilead Sciences in pact with drug trio |url=https://www.telegraphindia.com/business/gilead-sciences-in-pact-with-drug-trio/cid/776586 |access-date=27 June 2024 |work=The Telegraph |date=16 August 2006}}</ref>

In 2012, [[Hoffmann-La Roche|Roche]] signed a deal with Emcure for manufacturing its blockbuster anticancer drugs [[Trastuzumab|Herceptin]] and [[Rituximab|Mabthera]] in India.<ref name="auto1"/> Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.<ref>{{cite web |url=http://www.businessworld.in/businessworld/businessworld/content/Roche-Sell-Cheaper-Cancer-Drugs-India.html?print=yes |title=Roche to Sell Cheaper Cancer Drugs in India | Businessworld |access-date=2012-04-12 |url-status=dead |archive-url=https://archive.today/20120801012234/http://www.businessworld.in/businessworld/businessworld/content/Roche-Sell-Cheaper-Cancer-Drugs-India.html?print=yes |archive-date=2012-08-01 }}</ref>

In 2013, Emcure established a health foods venture in partnership with cricketer [[MS Dhoni]], and Dhoni was signed up as Emcure's brand ambassador.<ref>{{cite news |last1=Bhushan |first1=Ratna |title=MS Dhoni to sell health drink, energy bars in partnership with Emcure Pharmaceuticals |url=https://economictimes.indiatimes.com/industry/cons-products/food/ms-dhoni-to-sell-health-drink-energy-bars-in-partnership-with-emcure-pharmaceuticals/articleshow/18939753.cms |access-date=3 July 2024 |work=The Economic Times |date=13 March 2013}}</ref>

In 2014, [[Blackstone Inc.|Blackstone]] sold its 13% stake in Emcure to [[Bain Capital]].<ref>{{Cite web|url=http://archive.indianexpress.com/news/blackstone-to-sell-emcure-pharmaceuticals-stake-to-bain-capital/1209682/|title=Blackstone to sell Emcure Pharmaceuticals stake to Bain Capital - Indian Express|website=archive.indianexpress.com}}</ref>

In 2021, Emcure [[demerger|demerged]] its US-based business, including subsidiary Heritage Pharmaceuticals, into a new company called Avet Lifesciences.<ref name="crisil"/>

In 2024, Emcure launched its [[initial public offering]], and listed on NSE and BSE.<ref>{{cite news |last1=Podishetti |first1=Akash |title=Emcure Pharma shares debut with 31% premium over issue price |url=https://economictimes.indiatimes.com/markets/stocks/news/emcure-pharma-shares-debut-with-31-premium-over-issue-price/articleshow/111622266.cms |access-date=10 July 2024 |work=The Economic Times |date=10 July 2024}}</ref>

==Operations==
=== Indian plants ===
This is the list of manufacturing facilities based in India:<ref name=":0">{{Cite web|title=Manufacturing {{!}} Emcure Pharmaceuticals|url=https://www.emcure.com/manufacturing-overview/|access-date=2021-08-23|website=Emcure|date=29 July 2021|language=en-US|archive-date=3 August 2024|archive-url=https://web.archive.org/web/20240803125625/https://www.emcure.com/manufacturing-overview/|url-status=dead}}</ref>
*Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at [[Hinjawadi]], Pune. The plant manufactures solid oral formulations for the international regulated markets, but currently under [[FDA warning letter]]<ref name="fda.gov">{{cite web | url=https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/emcure-pharmaceuticals-limited-576961-08022019 | archive-url=https://web.archive.org/web/20190909071637/https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/emcure-pharmaceuticals-limited-576961-08022019 | url-status=dead | archive-date=9 September 2019 | title=Emcure Pharmaceuticals Limited - 576961 - 08/02/2019 | website=[[Food and Drug Administration]] | date=5 October 2020 }}</ref>
*Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has [[Freeze-drying|lyophilization]] and pfs capability, but currently under [[FDA warning letter]]<ref name="fda.gov"/>
*Oncology injectable facility at Hinjawadi, but currently under [[FDA warning letter]]<ref name="fda.gov"/>
*Solid Orals facilities at [[Jammu]] and [[Bhosari]]
*API facility at Kurkumbh- US FDA approved
*Biotech facility at Hinjawadi
*[[R&D|R&D Center]] at [[Gandhinagar]] and plant at [[Sanand]], [[Ahmedabad]].- Sanand facility is [[US FDA]] approved

=== US plant ===
USA - The company has a manufacturing facility and R&D center in [[East Brunswick, New Jersey]], USA.<ref name=":0" />

==Controversies and recalls==
In 2016, two former executives of Heritage Pharmaceuticals, an erstwhile division of Emcure, were among multiple entities charged by the [[United States Department of Justice]] (DOJ) with [[price fixing]] an antibiotic and an antidiabetic drug.<ref>{{cite news |title=2 ex-executives of Emcure's US arm accused of price fixing |url=https://www.business-standard.com/article/companies/former-executives-of-emcure-s-us-unit-accused-of-price-fixing-116121501097_1.html |access-date=27 June 2024 |work=Business Standard}}</ref> In 2019, the company entered into a [[deferred prosecution agreement]] with the DOJ. Under the terms of the settlement, Heritage agreed to pay over $7 million in penalty to the DOJ's Civil Division.<ref>{{Cite web|url=https://www.justice.gov/opa/pr/pharmaceutical-company-admits-price-fixing-violation-antitrust-law-resolves-related-false|title=Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations|date=31 May 2019|website=www.justice.gov}}</ref>

In 2022, HDT Bio Corp alleged that Emcure (through its subsidiary Gennova) stole the trade secrets of COVID-19 vaccine production in breach of its contract.<ref>{{Cite news | url=https://www.reuters.com/legal/government/lawsuit-says-indias-emcure-stole-covid-19-vaccine-secrets-ipo-2022-03-22/ | title=Lawsuit says India's Emcure stole COVID-19 vaccine secrets for IPO | newspaper=Reuters | date=22 March 2022 | last1=Brittain | first1=Blake }}</ref> The lawsuit was dismissed in 2024.<ref>{{cite news |last1=Pilla |first1=Viswanath |title=Emcure and its subsidiary Gennova settle legal dispute with HDT Bio over mRNA technology |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/emcure-and-its-subsidiary-gennova-settle-legal-dispute-with-hdt-bio-over-mrna-technology/articleshow/110354650.cms |access-date=27 June 2024 |work=The Economic Times |date=23 May 2024}}</ref>

In 2016, the USFDA gave a warning letter to Emcure for data integrity problems at Emcure plants.<ref>{{cite news |title=FDA Warns Indian Pharma Company Over Repeat Data Manipulation Violations |url=https://www.raps.org/News-and-Articles/News-Articles/2016/3/FDA-Warns-Indian-Pharma-Company-Over-Repeat-Data-M |access-date=27 June 2024 |work=raps.org}}</ref>

In 2010, [[Pfizer]] recalled three batches of an anti-bacterial product from the US market due to presence of ''Bacillus anthracis'', ''Penicillium chrysogenum'' & ''E. coli'' in some samples.<ref name="auto1">{{Cite web|url=https://economictimes.indiatimes.com/|title=Business News Today: Read Latest Business news, India Business News Live, Share Market & Economy News|website=The Economic Times}}</ref> [[Teva Pharmaceuticals|Teva]] recalled several batches of two products due to white tablets showing presence of ''Yersinia pestis'' in 2011.<ref>{{cite web |url=http://www.recalls.org/d2011-03.htm |title=March 2011 |access-date=2012-04-25 |url-status=dead |archive-url=https://web.archive.org/web/20110520185024/http://recalls.org/d2011-03.htm |archive-date=2011-05-20 }}</ref>

In 2022, Maharashtra FDA issued a circular to recall all the injections (500 mg /10 ml) manufactured by Emcure Pharmaceuticals, from across the country.<ref>{{cite news |title=FDA recalls Orofer FCM after Saifee patient's death |url=https://www.hindustantimes.com/cities/mumbai-news/fda-recalls-orofer-fcm-after-saifee-patient-s-death-101669229583763.html |access-date=27 June 2024 |work=Hindustan Times}}</ref>

In 2019, two injected drugs manufactured by Emcure were recalled because of microbial contamination. The drugs were both manufactured by Emcure Pharmaceuticals but were distributed in the US by Heritage Pharmaceuticals (now renamed Avet).<ref>[https://www.chemdiv.com/company/media/pharma-news/2019/emcure-injected-schizophrenia-drug-recalled-contamination-detected/ FDA asks Emcure to recall contaminated injectable drugs]</ref>

== See also ==

* [[Pharmaceutical industry]]
* [[Pharmaceutical industry in India]]
* [[Dr. Reddy's Laboratories]]
* [[Sun Pharma]]

== References ==
{{Reflist}}

== External links ==
*[https://emcure.com/ Emcure website]

{{Blackstone Companies}}
{{Authority control}}

[[Category:Manufacturing companies based in Pune]]
[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies established in 1983]]
[[Category:Indian companies established in 1983]]
[[Category:Indian brands]]
[[Category:1983 establishments in Maharashtra]]
[[Category:Bain Capital companies]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:2024 initial public offerings]]
[[Category:Multinational companies headquartered in India]]

Emcure Pharmaceuticals - Revision history

YvetteSawtell2 at 12:06, 19 February 2026